Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Shan I have some higher but as this started falling back I thought I’d wait to buy another bigger chunk and this seems the right time. I’m most excited by the cloud based system that will be charged ‘per use’ to hostipals. No idea what revenue that might bring in but at few dollars per use in the US not to mention the UK and China and others and this could be an almighty repeat revenue stream. Guidance is to get us to 30m turnover in 2 years which at say 20% margin should generate 6 million in profits. That values us at at least 50m or 50p ish a share. I know people always come up with these numbers and it’s normally a load of tosh but I believe it really could happen here. They have also hinted that they may make another acquisition which is interesting. Some minows do make it, especially in medical. Either way it’s an exciting time to be a share holder. I spoke to Trevor brown a while ago regarding fbdu and he basically said it was a slowish burner but to watch this space (that was a year ago) I’m sure you will get your money back and beyond. Don’t sell to early. Good Luck. SL
Some nice buys coming in . I'm waiting to sell another share then buy more here . Promising
probably just keep adding
1.5m in one go.. great sign. SL
To start a march forward, first target back to 4p+ Too much news flow to come this quarter.
500k in 2 chunks. Should pop up in trades anytime
Soul, yes baseline valuation here. Nothing has changed since 5-6p.... and all this to come this year... Flying Brands Ltd (LON:FBDU) is inching closer towards the global commercial roll-out of its key kidney stone medical imaging software StoneChecker. The company is awaiting clearance from the US Food and Drug Administration for StoneChecker, which is expected by the third quarter. Once approved, the group aims to launch the software in the US, India and China by the end of the year while commercial sales in the UK are expected to begin in the fourth quart
https://twitter.com/tmsreach/status/1046395091395522560?s=21
Liver Imaging Biometrics announce agreement to develop a diagnostic tool for liver surface nodularity. Imaging Biometrics , LLC ("IB"), a subsidiary of Flying Brands Limited (LON:FBDU), announces today that it has been awarded a development contract by the Board of Trustees of the University of Alabama ("UAB") to develop a product to quantify liver surface nodularity ("LSN") - a biomarker derived from routine computed tomographic ("CT") images, which allows prediction of cirrhosis decompensation and death. UAB will pay IB a fee to develop the software plus an additional fee for regulatory services.
Lenovo has created what it calls “cutting edge” artificial intelligence software that detects cancer cells within a liver tumor to help save lives as the vendor pushes deeper into the healthcare market using artificial intelligence. "Not only does this AI application detect that there is a tumor, but it shows me where the tumor is, the size of the tumor and if it is malignant versus benign," said David Mullin, worldwide Health Solution manager for Lenovo, in an interview with CRN at Lenovo Transform 2.0. Lenovo specifically built its LeHealth AI application for data scientists as part of the Lenovo intelligent Computing Orchestration (LiCO) solution that simplifies the management and use of distributed clusters for High Performance Computing workloads and AI model development.
And hopefully will start rising again soon with all the good news.
This used to be 6p
Good news SL hoping this comes good , looks very promising :)
A good chuck this am. On fda approval I can see this trebling up easily. Tiny mc at 2m. SL
The agreement is to develop the software only. The IP will be with UAB. There's nothing in the RNS that states IB will get royalties from any sales or that IB can act as a reseller.
Just like StoneChecker was redeveloped by a third party. The third party only got paid for development.
probably a nda so couldn't state figures. the fact its is going to lead to significant sales is interesting.
if they can develop the software to deal with liver problems then that is big time. they can start with mine
Any thoughts on today’s rns??
In my opinion it won’t rerate till the fda approval is given and sales start. It should climb back to 6p which is once was
What's going on ? Volumes of buys and over 6% drop in sp ? Bloody hell
https://youtu.be/BF9KRrMEYv8
As good as it gets.
Added
Response from David Smith to the questions raised by Elartu: Thanks for the question. I’ve seen this a number of times and it comes from a fundamental misunderstanding of how the 510k system works. First of all, the easy part, the lack of TexRad IP is irrelevant as far as FDA goes. The 510k system requires you to nominate a ‘predicate’ , or preceding device that also has a 510k to which you will compare your product. All that you need to do is to demonstrate safety and efficacy. Safety is normally demonstrated by showing that you produce your device to the ISO standards (usually ISO 13485) in a validated Quality System. Efficacy is demonstrated by comparing the performance of your device to something that is already on the market. In this case we demonstrated against an array of products, since there is nothing quite like the StoneChecker software. We submitted a package that we believe demonstrates that the product can reliably predict the likelihood that sound waves will break up the kidney stone during a lithotripsy procedure by using data from a few hundred patients who had undergone lithotripsy. The presence or absence of TexRad is a bit of a red herring. Let me give you an analogy. Let’s say we were trying to get a 510k for a new type of electronic thermometer. We would probably choose an old fashioned mercury thermometer to compare - our predicate device. We would simply run bench tests to show that the temperatures measured by the electronic thermometer matches those recorded by the mercury filled thermometer. It would be irrelevant that the electronic thermometer featured a Samsung thermistor (TexRad), or that it had IP coverage, since the real magic in this case would be the way we used the thermistor, and our proprietary software, not the thermistor. In fact, this would give us an advantage since we could always substitute out a different thermistor if we later found one that performed equally well for less money. In summary we believe we are well placed to be cleared for marketing before the end of the year. Our package was accepted by FDA on August 22.